PSY37 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 600/800mg Daily as Therapy for Imatinib Failing Chronic Myeloid Leukemia (CML)

Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.571
https://www.valueinhealthjournal.com/article/S1098-3015(12)00636-5/fulltext
Title : PSY37 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 600/800mg Daily as Therapy for Imatinib Failing Chronic Myeloid Leukemia (CML)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)00636-5&doi=10.1016/j.jval.2012.03.571
First page : A105
Section Title : Systemic Disorders/Conditions
Open access? : No
Section Order : 36
Categories :
Tags :
Regions :
ViH Article Tags :